IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v42y2019i5d10.1007_s40264-018-0759-7.html
   My bibliography  Save this article

Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance

Author

Listed:
  • Lisa Harinstein

    (Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration)

  • Dipti Kalra

    (Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration)

  • Cindy M. Kortepeter

    (Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration)

  • Monica A. Muñoz

    (Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration)

  • Eileen Wu

    (Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration)

  • Gerald J. Dal Pan

    (Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration)

Abstract

Introduction and Objective Adverse event reports from industry-sponsored programs, such as patient support programs, have contributed to a rise in the number of individual case safety reports in the US Food and Drug Administration Adverse Event Reporting System database. This study aimed to characterize individual case safety reports from industry-sponsored program and non-industry-sponsored program sources and compare their usefulness in safety signal detection. Methods Individual case safety reports of six drug and biological products were identified in the Food and Drug Administration Adverse Event Reporting System database between the date of Food and Drug Administration product approval and the first quarter of 2017. A random subset of industry-sponsored program and non-industry-sponsored program individual case safety reports were then compared to identify differences in reporters, outcomes, data completeness, and usefulness. The ‘usefulness’ of individual case safety reports was assessed by manually reviewing the availability of key information in the narrative (e.g., temporality, comorbidities). Results Compared with non-industry-sponsored program reports, more industry-sponsored program reports were associated with a serious outcome (51.4% vs. 58.8%, p = 0.02) and were reported by consumers (35.5% vs. 50.4%, p

Suggested Citation

  • Lisa Harinstein & Dipti Kalra & Cindy M. Kortepeter & Monica A. Muñoz & Eileen Wu & Gerald J. Dal Pan, 2019. "Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance," Drug Safety, Springer, vol. 42(5), pages 649-655, May.
    • Handle: RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-018-0759-7
    DOI: 10.1007/s40264-018-0759-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0759-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-018-0759-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Monica A. Muñoz & Gerald J. Dal Pan, 2019. "The Impact of Litigation-Associated Reports on Signal Identification in the US FDA’s Adverse Event Reporting System," Drug Safety, Springer, vol. 42(10), pages 1199-1201, October.
    2. Kathryn Marwitz & S. Christopher Jones & Cindy M. Kortepeter & Gerald J. Dal Pan & Monica A. Muñoz, 2020. "An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System," Drug Safety, Springer, vol. 43(5), pages 457-465, May.
    3. Peter Arlett, 2019. "Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance," Drug Safety, Springer, vol. 42(5), pages 581-582, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-018-0759-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.